High sensitivity of the Hematoflow™ solution for chronic myelomonocytic leukemia screening

Background: Accumulation of classical monocytes CD14++CD16- (also called MO1) ≥94% can accurately distinguish chronic myelomonocytic leukemia (CMML) from reactive monocytosis. The HematoFlow™ solution, able to quantify CD16 negative monocytes, could be a useful tool to manage monocytosis which remains a common issue in routine laboratories. Methods: Classical monocytes were quantified from 153 whole blood samples collected on EDTA using both flow cytometry methods, either MO1 percentage determination by the multiparameter assay previously published and regarded here as the reference method, or CD16 negative monocyte percentage determination by the means of HematoFlow™. Results: Both methods of classical monocyte percentage determination were highly and significantly correlated (r=0.87, p